Alphamab Oncology reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CNY 218.77 million compared to CNY 166.85 million a year ago. Net loss was CNY 210.59 million compared to CNY 325.72 million a year ago.

Basic loss per share from continuing operations was CNY 0.22 compared to CNY 0.35 a year ago. Diluted loss per share from continuing operations was CNY 0.22 compared to CNY 0.35 a year ago.